

Corporate Medical Policy

Salivary Hormone Testing AHS – G2120

File Name: salivary_hormone_testing
Origination: 01/01/2019
Last CAP Review: 03/2021
Next CAP Review: 03/2022
Last Review: 04/2021

Description of Procedure or Service

Definition

Testing of saliva has been proposed as a noninvasive method to measure free (unbound to carrier proteins and thus active) steroid hormones, including estrogen, progesterone, androgens, and cortisol, for diagnosis of hormonal imbalance and administration of individualized hormone replacement therapy (ACOG & ASRM, 2012).

Hypercortisolism can occur in several disorders, including Cushing's syndrome (pituitary hypersecretion of corticotropin/ACTH), or as a result of glucocorticoid administration resulting in obesity, hypertension, menstrual irregularity, and glucose intolerance (Lacroix, Feelders, Stratakis, & Nieman, 2015; Nieman et al., 2008; L. K. Nieman, 2019a; Quddusi, Browne, Toivola, & Hirsch, 1998).

Related Policies:

Hormonal Testing in Females
Hormonal Testing in Males

******Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.***

Policy

BCBSNC will provide coverage for salivary hormone testing when it is determined the medical criteria or reimbursement guidelines below are met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When salivary hormone testing is covered

Reimbursement for Late Night Salivary Cortisol testing is allowed for diagnosing Cushing's Syndrome.

When salivary hormone testing is not covered

Salivary Hormone Testing AHS – G2120

Reimbursement is not allowed for salivary hormone testing for the screening, diagnosis, and/or monitoring of menopause, infertility, endometriosis, polycystic ovary disease (PCOS), premenstrual syndrome, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or diseases related to aging.

Salivary hormone tests include but are not limited to the following:

- Estrogen
- Melatonin
- Progesterone
- Testosterone
- DHEA
- Cortisol

Policy Guidelines

Background

Testing of hormone levels in the saliva has been proposed as a noninvasive method to measure free (unbound to carrier proteins and thus active) steroid hormones (estrogen, progesterone, androgens, cortisol, etc) for diagnosis of hormonal imbalance and administration of individualized hormone replacement therapy (ACOG & ASRM, 2012). Saliva measurements are thought to represent concentration of an unconjugated steroid hormone well as unconjugated steroids diffuse freely into saliva. Conjugated steroids will often show significant decreases in concentration because their filtration process into the saliva is limited. This is what causes hormones such as cortisol, estradiol, and testosterone to approximate concentrations well and a hormone such as DHEA to represent concentrations poorly (Wood, 2009).

Salivary hormone level testing is often recommended by bioidentical hormone vendors as a means of providing individualized therapy. However, individualized testing and monitoring is only useful when a narrow therapeutic window exists for a drug or a drug class. Steroid hormones such as estrogen and progesterone do not meet these criteria and do not require individualized testing (ACOG & ASRM, 2012; Conaway, 2011). Furthermore, there is no evidence that hormonal levels in saliva are biologically meaningful. Saliva is an ultra-filtrate of the blood and in theory should be amenable to testing for free concentrations of hormones, however salivary testing does not appear to be accurate or precise method of hormone testing (Flyckt et al., 2009; Lewis, McGill, Patton, & Elder, 2002). Studies suggest that salivary assessments of hormone levels are inaccurate and do not correlate with levels determined from serum (Conaway, 2011) as there is large within patient variability in salivary hormone concentrations, especially when exogenously administered hormones are given (Hardiman, Thomas, Osgood, Vlassopoulou, & Ginsburg, 1990; Klee & Hesser, 2000; Lewis et al., 2002; Meulenberg, Ross, Swinkels, & Benraad, 1987; Wren et al., 2000). Salivary hormone levels often fluctuate with factors such as circadian rhythm and frequently do not correlate well with serum levels of hormones (Wood, 2009).

Salivary hormone measurement may be utilized for many purposes. Menopause occurs due to changing hormone levels, mainly estrogen. In general, women experience menopause at a mean age of 51 years, with most becoming menopausal between 45 and 55. Menopausal hormone therapy (MHT, estrogen alone or combined with a progestin) is used for management of menopausal symptoms and is highly effective for symptoms, such as hot flashes and vaginal atrophy. In some cases, MHT may be used for the mood lability that many women experience during the menopausal transition (Martin & Barbieri, 2020; Taylor & Manson, 2011). There are few indications for the measurement of hormone levels to evaluate success of therapy when treating a postmenopausal woman with hormones. If treatment is initiated for symptom control, therapy should be titrated to the alleviation of symptoms, not a laboratory value (ACOG & ASRM, 2012). A salivary hormone test has been developed by Genova Diagnostics, which evaluates levels of hormones in males and females during perimenopause, menopause, and andropause (male menopause) (Genova_Diagnostics, 2020).

Salivary Hormone Testing AHS – G2120

One of the primary hormones that diffuses freely into saliva and can be well-approximated by salivary measurements is cortisol. Cortisol is a steroid hormone that is produced due to stress. Salivary flow rate does not affect cortisol concentration, and salivary cortisol correlates well with serum-free cortisol. This property can be used to identify adrenal insufficiencies and other related disorders (L. K. Nieman, 2019b). For example, the presence of Cushing's syndrome (CS) is suggested by signs of hypercortisolism, such as proximal myopathy, facial plethora, and wide purplish striae. However, none of these are pathognomonic, and many are nonspecific (such as obesity or hypertension). As a result, the diagnosis must be confirmed by biochemical tests, one of which is a salivary cortisol measurement (L. K. Nieman, 2020). The recurrence of hypercortisolemia after an initial treatment for CS seems to be predicted earlier by late night salivary cortisol (LNSC) testing compared to urinary free cortisol excretion (Fleseriu, Hamrahian, Hoffman, Kelly, & Katznelson, 2016).

Analytical Validity

Multiple proprietary tests are available for salivary hormone testing. Tests such as ZRT and UnikeyHealth ask the user to submit saliva samples and send the specimen to the proprietary lab where it can be analyzed. Labs will typically use an immunoassay-based method, such as an enzyme-linked immunosorbent assay (ELISA) or enzyme immunoassay (EIA), to assess the concentration of hormones, such as estradiol or progesterone. Others may use an automated competitive electrochemiluminescence immunoassay for LNSC measurement (Spence et al., 2018). The results are compiled into a report listing the concentrations of each hormone as well as comments on abnormal amounts. These tests are often marketed to post-menopausal women who desire to have an assessment of hormones like estrogen, progesterone, DHEA, testosterone, estriol, and cortisol (UniKey, 2018; ZRTLAB, 2018). Moreover, another proprietary test proposes that conditions such as multiple sclerosis (MS) can be assessed through irregularities in melatonin (Genova, 2019a). However, not only is melatonin not widely measured through saliva, but there is currently no compelling data for whether administering melatonin has any utility with dealing with MS; there has been far too little published data with human subjects to draw any conclusions (Wurtman, 2017; R. Wurtman, 2019). Osteoporosis is another condition that tests may purportedly be able to screen for with saliva (Genova, 2019b). However, this test may be of limited utility as the risks of hormone therapy may outweigh the benefits (Rossouw et al., 2002).

Salivary cortisol was first measured by direct radioimmunoassay (RIA) in 1978, but more accurate cortisol immunoassays have now been developed; however, these assays are often limited due to poor specificity (El-Farhan, Rees, & Evans, 2017). Further, late at night, cortisol levels may fall below detection limits for some RIA testing methods. Liquid chromatography with tandem mass spectrometry (LC-MS-MS) has also been used for the detection of salivary cortisol. Schiffer et al. (2019) developed a novel LC-MS/MS assay to identify androgens in saliva samples with appropriate sensitivity. Prior, Li, Li, and Kellermann (2018) was able to utilize the same technique (LC-MS/MS) to accurately quantify three estrogens (estrone E1, estradiol E2, and estriol E3) in an assay with an accuracy of 98.9-112.4% and precision of ($\leq 7.4\%$) as a hopeful alternative to blood samples. However, this field continues to face limitations due to poorly standardized assays and a lack of a single, validated reference range (El-Farhan et al., 2017).

Initial diagnostic tests for hypercortisolism should be highly sensitive, even if the diagnosis may be excluded later. Late night salivary cortisol (LNSC) is a first-line diagnostic test for CS as indicated by the approach outlined by the 2008 Endocrine Society (Nieman et al., 2008) and others (Hinojosa-Amaya, Varlamov, McCartney, & Fleseriu, 2019). LNSC measurements are obtained at least twice because the hypercortisolism in CS may be variable. Two measurements must be abnormal for the test to be considered abnormal; this may be especially difficult for patients with fluctuating disease. The diagnosis of CS is established when at least two different first-line tests (such as LNSC and 24-hour urinary cortisol excretion) are abnormal. Once the diagnosis is established, additional evaluation is done to identify the cause of the hypercortisolism (L. K. Nieman, 2020).

Salivary Hormone Testing AHS – G2120

A locally modified RIA assay was developed by Nunes et al. (2009) and measured LNSC in obese patients with a current or past diagnosis of CS. The assay was able to diagnose a recurrence of CS with a sensitivity of 90% and a specificity of 91.8%; it was also reported that “A threshold of 12 nmol/liter yielded 100% sensitivity and specificity in overt Cushing's syndrome” (Nunes et al., 2009).

Clinical Validity and Utility

A study by Lewis et al. (2002) focusing on salivary progesterone measurements found major variation when a progesterone cream was applied to several post-menopausal women. Salivary measurements were collected at 0, 1, 3, 4, 7, and 8 weeks. The average baseline for the 20 mg/g cream group was found to be 0.25 ± 0.12 nmol/L, but the measurement at 1 week was 82.11 ± 104.52 nmol/L (Lewis et al., 2002); similar enormous variations were found at 3 and 7 weeks, as well as the 40 mg/gm cream group. In contrast, the placebo group's baseline was 0.43 ± 0.21 and 0.38 ± 0.20 in week 8 (Lewis et al., 2002). The finding with inconsistent salivary progesterone levels was even found among premenopausal women obtaining *in vitro* fertilization (IVF); on the other hand, salivary estradiol was found to be correlative to serum-based assessment, and could be a less invasive alternative to blood draws for ovarian stimulation during IVF cycles (Sakkas et al., 2020).

LNSC measurements were found to be concordant with the 24-hour urine test, with 97% concordance at ≥ 4 nmol/L and 69% concordance at ≥ 10 nmol/L. However, the tests were stated to be “equivalent” at the more sensitive cutoff of 4 nmol/L. The authors concluded that due to the concordance of the salivary test with the urine test, the salivary test should replace the urinary test as the frontline test for Cushing's syndrome (Doi, Clark, & Russell, 2013). Another study found LNSC to be 100% sensitive and 98% specific at a cut-off of 2.4 nmol/L (Antonelli, Ceccato, Artusi, Marinova, & Plebani, 2015). Both cortisol and its metabolite cortisone were tested as cortisone is a significant source of interference in certain immunoassays. The variation between and within runs were both under 10%, the method was linear up to 55.4 nmol/L for cortisol, and the lower limit of quantification was 0.51 nmol/L for cortisol (Antonelli et al., 2015).

A study measured the utility of salivary testosterone and cortisol concentrations in 71 junior athletes (26 females and 45 males) in response to stress. The researchers compared results of salivary samples to capillary blood samples taken at the same time; while blood samples showed an increase in both testosterone and cortisol concentrations in both sexes, salivary samples showed no change in testosterone or cortisol levels (Crewther, Obminski, Orysiak, & Al-Dujaili, 2018). This may suggest that salivary hormone testing in these populations is not as efficient as other methods.

Valassi et al. (2017) analyzed diagnostic data from 1341 CS patients in the European Registry on Cushing's syndrome (ERCUSYN) and noted that of the three main first-line CS diagnostic tests, the urinary free cortisol test was performed in 78% of patients as a first-line testing method, overnight 1 mg dexamethasone suppression test was performed in 60% of patients, and LNSC was performed in only 25% of patients. This shows that LNSC may not be used as frequently as other testing methods for a first-line diagnosis of CS.

Salivary testing for cortisol could also prove useful in occupational settings as a parameter for stress. Oldenburg and Jensen (2019) conducted a study on merchant ship crew, and found that after adjustment, average salivary cortisol level was positively associated with “acute shipboard stressors, namely the average current working time ($p=.050$) and the average number of terminals that had been served during the last 7 days ($p=0.008$).” This laboratory data is essential in all fields wherein professionals experience high levels of stress, so that measures can be taken to create a positive working environment.

Applicable State/Federal Regulations

Salivary hormones may be measured by multiple tests. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests

Salivary Hormone Testing AHS – G2120

under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

Guidelines and Recommendations

American Association of Clinical Endocrinologists (AACE) (Goodman, Cobin, Ginzburg, Katz, & Woode, 2011)

The AACE has noted salivary hormone level testing as recommended by certain proponents to provide individualized therapy. However, these methods are not FDA or CLIA approved, and factors such as hydration and circadian rhythm may influence the concentration of hormones within a subject. Standardization is difficult, and even though standardized blood tests do exist, it is of limited clinical utility because measuring hormone levels in postmenopausal women has no predictive value on what the normal levels should be. A salivary measurement cannot be used to correct the levels of sex hormones. (Goodman et al.,).

American College of Obstetricians and Gynecologists (ACOG) and the American Society of Reproductive Medicine Practice Committee (ASRM) [(ACOG & ASRM, 2012) reaffirmed 2020

ACOG and ASRM released joint guidelines on compounded hormone therapy that stated salivary hormone testing had no evidence to support its biological utility and that testing the hormone levels were neither accurate nor precise. The guidelines stated that salivary hormone testing had large intra-patient variability depending on factors such as diet and that saliva did not provide a reasonable representation of serum hormone levels. Saliva may be contaminated with other cell types, contains lower concentration of hormones than serum, and impossible to reliably test for a representative result. The guidelines concluded that evidence is inadequate to support an individualized hormone therapy based on salivary, serum, or urine testing (ACOG & ASRM, 2012).

Finally, the guideline wrote that “there is no evidence that hormonal levels in saliva are biologically meaningful.” (ACOG & ASRM, 2012)

North American Menopausal Society (NAMS, 2012, 2017)

The NAMS addressed salivary hormone testing with regards to MHT, stating that salivary hormone testing is “inaccurate and unreliable.” The NAMS further notes that the levels in serum, saliva, and tissue are “markedly different” and alludes to the FDA’s statement that there is “no scientific basis for using saliva testing to adjust hormone levels” (NAMS, 2012).

The NAMS also addressed salivary hormone testing in the context of compounded HT (hormone therapy), which would include estradiol, estrone, and micronized progesterone (MP), but corroborates that salivary testing for HT is considered “unreliable because of differences in hormone pharmacokinetics and absorption, diurnal variation, and inter-individual and intraindividual variability” (NAMS, 2017).

Endocrine Society

The ES states that “salivary hormone assays are not standardized, do not have independent quality control programs, and lack an accepted reference range.” The Society further mentions that there is no scientific evidence that a correlation exists between symptoms and salivary hormones. Assessment or monitoring of hormone therapy lacks evidence, and the American College of Obstetricians and Gynecologists, the North American Menopausal Society, and the Endocrine Society all recommend against salivary hormone testing (Santoro et al., 2016).

The ES also recommends a test of at least two LNSC measurements for diagnosis of Cushing’s Syndrome. If a patient has eucortisolism after a transsphenoidal selective adenectomy (TSS), a measurement of late-night salivary or serum cortisol is recommended (Nieman, 2015; Nieman et al., 2008).

Salivary Hormone Testing AHS – G2120

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 82530, 82533, 82626, 82627, 82670, 82671, 82672, 82677, 82679, 82681, 84144, 84402, 84403, 84410, S3650

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

ACOG, & ASRM. (2012). Compounded bioidentical menopausal hormone therapy. *Fertil Steril*, 98(2), 308-312. doi:10.1016/j.fertnstert.2012.06.002

Antonelli, G., Ceccato, F., Artusi, C., Marinova, M., & Plebani, M. (2015). Salivary cortisol and cortisone by LC-MS/MS: validation, reference intervals and diagnostic accuracy in Cushing's syndrome. *Clin Chim Acta*, 451(Pt B), 247-251. doi:10.1016/j.cca.2015.10.004

Conaway, E. (2011). Bioidentical hormones: an evidence-based review for primary care providers. *J Am Osteopath Assoc*, 111(3), 153-164.

Crewther, B. T., Obminski, Z., Orysiak, J., & Al-Dujaili, E. A. S. (2018). The utility of salivary testosterone and cortisol concentration measures for assessing the stress responses of junior athletes during a sporting competition. *J Clin Lab Anal*, 32(1). doi:10.1002/jcla.22197

Doi, S. A., Clark, J., & Russell, A. W. (2013). Concordance of the late night salivary cortisol in patients with Cushing's syndrome and elevated urine-free cortisol. *Endocrine*, 43(2), 327-333. doi:10.1007/s12020-012-9855-0

El-Farhan, N., Rees, D. A., & Evans, C. (2017). Measuring cortisol in serum, urine and saliva - are our assays good enough? *Ann Clin Biochem*, 54(3), 308-322. doi:10.1177/0004563216687335

Fleseriu, M., Hamrahian, A. H., Hoffman, A. R., Kelly, D. F., & Katznelson, L. (2016). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: DIAGNOSIS OF RECURRENCE IN CUSHING DISEASE. *Endocr Pract*, 22(12), 1436-1448. doi:10.4158/ep161512.Dscr

Flyckt, R. L., Liu, J., Frasure, H., Wekselman, K., Buch, A., & Kingsberg, S. A. (2009). Comparison of salivary versus serum testosterone levels in postmenopausal women receiving transdermal testosterone supplementation versus placebo. *Menopause*, 16(4), 680-688. doi:10.1097/gme.0b013e318199d5c4

Genova. (2019a). Comprehensive Melatonin Profile. Retrieved from <https://www.gdx.net/product/comprehensive-melatonin-test-saliva>

Genova. (2019b). Rhythm™. Retrieved from <https://www.gdx.net/product/rhythm-hormone-test-saliva>

Genova_Diagnostics. (2020). Menopause™ The Original Genova Salivary Sex-Hormone Test. Retrieved from <https://www.gdx.net/product/menopause-hormone-test-saliva>

Salivary Hormone Testing AHS – G2120

- Goodman, N. F., Cobin, R. H., Ginzburg, S. B., Katz, I. A., & Woode, D. E. (2011). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. *Endocr Pract*, *17 Suppl 6*, 1-25.
- Hardiman, P., Thomas, M., Osgood, V., Vlassopoulou, V., & Ginsburg, J. (1990). Are estrogen assays essential for monitoring gonadotropin stimulant therapy? *Gynecol Endocrinol*, *4*(4), 261-269.
- Hinojosa-Amaya, J. M., Varlamov, E. V., McCartney, S., & Fleseriu, M. (2019). Hypercortisolemia Recurrence in Cushing's Disease; a Diagnostic Challenge. *Front Endocrinol (Lausanne)*, *10*, 740. doi:10.3389/fendo.2019.00740
- Klee, G. G., & Hesser, D. W. (2000). Techniques to measure testosterone in the elderly. *Mayo Clin Proc*, *75 Suppl*, S19-25.
- Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015). Cushing's syndrome. *Lancet*, *386*(9996), 913-927. doi:10.1016/s0140-6736(14)61375-1
- Lewis, J. G., McGill, H., Patton, V. M., & Elder, P. A. (2002). Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. *Maturitas*, *41*(1), 1-6.
- Li, X. S., Li, S., & Kellermann, G. (2018). Simultaneous determination of three estrogens in human saliva without derivatization or liquid-liquid extraction for routine testing via miniaturized solid phase extraction with LC-MS/MS detection. *Talanta*, *178*, 464-472. doi:10.1016/j.talanta.2017.09.062
- Martin, K., & Barbieri, R. (2020, August 31). Menopausal hormone therapy: Benefits and risks. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/menopausal-hormone-therapy-benefits-and-risks>
- Meulenberg, P. M., Ross, H. A., Swinkels, L. M., & Benraad, T. J. (1987). The effect of oral contraceptives on plasma-free and salivary cortisol and cortisone. *Clin Chim Acta*, *165*(2-3), 379-385.
- NAMS. (2012). The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause*, *19*(3), 257-271. doi:10.1097/gme.0b013e31824b970a
- NAMS. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause: The Journal of the North American Menopause Society*, *24*(7), 728-753. doi:10.1097/GME.0000000000000921
- Nieman. (2015). Cushing's syndrome: update on signs, symptoms and biochemical screening. *Eur J Endocrinol*, *173*(4), M33-38. doi:10.1530/eje-15-0464
- Nieman, Biller, B. M., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008). The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*, *93*(5), 1526-1540. doi:10.1210/jc.2008-0125
- Nieman, L. K. (2019a, November 12). Causes and pathophysiology of Cushing's syndrome. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/causes-and-pathophysiology-of-cushings-syndrome>
- Nieman, L. K. (2019b, September 29). Measurement of cortisol in serum and saliva. Retrieved from <https://www.uptodate.com/contents/measurement-of-cortisol-in-serum-and-saliva>
- Nieman, L. K. (2020, May 29). Establishing the diagnosis of Cushing's syndrome. *UpToDate*. Retrieved from <https://www.uptodate.com/contents/establishing-the-diagnosis-of-cushings-syndrome>

Salivary Hormone Testing AHS – G2120

- Nunes, M. L., Vattaut, S., Corcuff, J. B., Rault, A., Loiseau, H., Gatta, B., . . . Tabarin, A. (2009). Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients. *J Clin Endocrinol Metab*, *94*(2), 456-462. doi:10.1210/jc.2008-1542
- Oldenburg, M., & Jensen, H. J. (2019). Saliva cortisol level as a strain parameter for crews aboard merchant ships. *Chronobiol Int*, *36*(7), 1005-1012. doi:10.1080/07420528.2019.1604540
- Quddusi, S., Browne, P., Toivola, B., & Hirsch, I. B. (1998). Cushing syndrome due to surreptitious glucocorticoid administration. *Arch Intern Med*, *158*(3), 294-296.
- Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., . . . Ockene, J. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *Jama*, *288*(3), 321-333.
- Rubio-Tapia, A., Hill, I. D., Kelly, C. P., Calderwood, A. H., & Murray, J. A. (2013). ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol*, *108*(5), 656-676; quiz 677. doi:10.1038/ajg.2013.79
- Sakkas, D., Howles, C. M., Atkinson, L., Borini, A., Bosch, E. A., Bryce, C., . . . Alper, M. M. (2020). A multi-centre international study of salivary hormone oestradiol and progesterone measurements in ART monitoring. *Reprod Biomed Online*. doi:10.1016/j.rbmo.2020.10.012
- Santoro, N., Braunstein, G. D., Butts, C. L., Martin, K. A., McDermott, M., & Pinkerton, J. V. (2016). Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. *J Clin Endocrinol Metab*, *101*(4), 1318-1343. doi:10.1210/jc.2016-1271
- Schiffer, L., Adaway, J. E., Arlt, W., & Keevil, B. G. (2019). A liquid chromatography-tandem mass spectrometry assay for the profiling of classical and 11-oxygenated androgens in saliva. *Ann Clin Biochem*, *56*(5), 564-573. doi:10.1177/0004563219847498
- Spence, K., McKeever, E., Graham, U., Irwin, S., Neely, J., McAlister, C., . . . McDonnell, M. (2018). Salivary cortisol determination using the Roche generation II assay. <https://www.endocrine-abstracts.org/ea/0059/ea0059p007>
- Taylor, H. S., & Manson, J. E. (2011). Update in hormone therapy use in menopause. *J Clin Endocrinol Metab*, *96*(2), 255-264. doi:10.1210/jc.2010-0536
- UniKey. (2018). Retrieved from <https://unikeyhealth.com>
- Valassi, E., Franz, H., Brue, T., Feelders, R. A., Netea-Maier, R., Tsagarakis, S., . . . Trainer, P. J. (2017). Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. *Eur J Endocrinol*, *176*(5), 613-624. doi:10.1530/eje-16-0967
- Wood, P. (2009). Salivary steroid assays - research or routine? *Ann Clin Biochem*, *46*(Pt 3), 183-196. doi:10.1258/acb.2008.008208
- Wren, B. G., McFarland, K., Edwards, L., O'Shea, P., Sufi, S., Gross, B., & Eden, J. A. (2000). Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. *Climacteric*, *3*(3), 155-160.
- Wurtman. (2017). Multiple Sclerosis, Melatonin, and Neurobehavioral Diseases. *Front Endocrinol (Lausanne)*, *8*, 280. doi:10.3389/fendo.2017.00280
- Wurtman, R. (2019, April 30). Physiology and available preparations of melatonin. Retrieved from <https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin>
- ZRTLAB. (2018). Retrieved from <https://www.zrtlab.com>

Salivary Hormone Testing AHS – G2120

Specialty Matched Consultant Advisory Panel review 3/20

Medical Director Review 3/2021

Medical Director Review 4/2021

Policy Implementation/Update Information

- 1/1/19 New policy developed. BCBSNC will provide coverage for salivary hormone testing when it is determined to be medically necessary because the medical criteria and guidelines are met. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019. (an)
- 5/14/19 Reviewed by Avalon 1st Quarter 2019 CAB. Minor changes to Description Section. Revised NonCovered statement to read: “Salivary hormone testing for the screening, diagnosis, and/or monitoring of menopause, infertility, endometriosis, polycystic ovary disease (PCOS), premenstrual syndrome, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or diseases related to aging is considered not medically necessary.” Added Cortisol to list of NonCovered tests. Policy Guidelines section and References updated. Medical Director review 4/2019. **Policy noticed 5/14/2019 for effective date 7/16/2019.** (an)
- 10/29/19 Wording in the Policy, When Covered, and/or Not Covered section(s) changed from Medical Necessity to Reimbursement language, where needed. (gm)
- 03/31/20 Specialty Matched Consultant Advisory Panel 3/18/20. No change in policy statement. (eel)
- 5/12/20 Reviewed by Avalon for 1st Quarter 2020 CAB. Updated Description and Policy Guidelines section. Added references. No change to policy statement. Medical Director review 4/2020. (eel)
- 3/31/21 Specialty Matched Consultant Advisory Panel 3/9/21. No change to policy statement. (bb)
- 5/4/21 Reviewed by Avalon 1st Quarter 2021 CAB. Updated Description and Policy Guidelines section. Billing/Coding section updated: codes 82530 and 82533 corrected due to typographical error, code 2681 added. Updated references. No change to policy statement. Medical Director review 4/2021. (bb)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.